NL301159I2 - bimekizumab - Google Patents
bimekizumabInfo
- Publication number
- NL301159I2 NL301159I2 NL301159C NL301159C NL301159I2 NL 301159 I2 NL301159 I2 NL 301159I2 NL 301159 C NL301159 C NL 301159C NL 301159 C NL301159 C NL 301159C NL 301159 I2 NL301159 I2 NL 301159I2
- Authority
- NL
- Netherlands
- Prior art keywords
- bimekizumab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161432814P | 2011-01-14 | 2011-01-14 | |
| PCT/GB2012/050050 WO2012095662A1 (en) | 2011-01-14 | 2012-01-11 | Antibody molecules which bind il-17a and il-17f |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL301159I1 NL301159I1 (nl) | 2022-01-26 |
| NL301159I2 true NL301159I2 (nl) | 2022-02-10 |
Family
ID=45496193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301159C NL301159I2 (nl) | 2011-01-14 | 2022-01-19 | bimekizumab |
Country Status (36)
| Country | Link |
|---|---|
| US (5) | US8580265B2 (nl) |
| EP (2) | EP3219728A1 (nl) |
| JP (2) | JP6028737B2 (nl) |
| KR (1) | KR101950306B1 (nl) |
| CN (1) | CN103384682B (nl) |
| AR (2) | AR084845A1 (nl) |
| AU (1) | AU2012206431B2 (nl) |
| BR (1) | BR112013017951B1 (nl) |
| CA (1) | CA2823812C (nl) |
| CL (1) | CL2013002044A1 (nl) |
| CO (1) | CO6781516A2 (nl) |
| CY (1) | CY1119055T1 (nl) |
| DK (1) | DK2663577T3 (nl) |
| EA (1) | EA037071B1 (nl) |
| ES (1) | ES2632583T3 (nl) |
| FI (1) | FIC20220002I1 (nl) |
| FR (1) | FR22C1000I2 (nl) |
| HR (1) | HRP20171034T1 (nl) |
| HU (1) | HUS2200001I1 (nl) |
| IL (1) | IL227347B (nl) |
| LT (2) | LT2663577T (nl) |
| MA (1) | MA34907B1 (nl) |
| ME (1) | ME02734B (nl) |
| MX (1) | MX341489B (nl) |
| MY (1) | MY162790A (nl) |
| NL (1) | NL301159I2 (nl) |
| PL (1) | PL2663577T3 (nl) |
| PT (1) | PT2663577T (nl) |
| RS (1) | RS56298B1 (nl) |
| SG (2) | SG10201510762YA (nl) |
| SI (1) | SI2663577T1 (nl) |
| TN (1) | TN2013000292A1 (nl) |
| TW (1) | TWI511978B (nl) |
| UA (1) | UA110358C2 (nl) |
| WO (1) | WO2012095662A1 (nl) |
| ZA (1) | ZA201306080B (nl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0620729D0 (en) * | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| GB0807413D0 (en) * | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
| RU2012149227A (ru) | 2010-05-20 | 2014-06-27 | Аблинкс Нв | Биологические материалы, относящиеся к her3 |
| ES2632583T3 (es) | 2011-01-14 | 2017-09-14 | Ucb Biopharma Sprl | Anticuerpo que se une a IL-17A e IL-17F |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| IN2014DN09417A (nl) | 2012-05-10 | 2015-07-17 | Bioatla Llc | |
| GB201310544D0 (en) | 2013-06-13 | 2013-07-31 | Ucb Pharma Sa | Obtaining an improved therapeutic ligand |
| WO2015070697A1 (zh) * | 2013-11-18 | 2015-05-21 | 上海恒瑞医药有限公司 | Il-17a结合物及其用途 |
| BR112016018980A2 (pt) | 2014-02-21 | 2017-10-10 | Genentech Inc | método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica |
| TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
| WO2016123329A2 (en) | 2015-01-28 | 2016-08-04 | Genentech, Inc. | Gene expression markers and treatment of multiple sclerosis |
| MX2018005031A (es) * | 2015-10-27 | 2018-06-13 | Ucb Biopharma Sprl | Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f). |
| RU2680011C2 (ru) | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
| EA201990673A1 (ru) | 2016-09-14 | 2019-08-30 | Бэйцзин Ханми Фарм. Ко., Лтд. | Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты |
| EP3592771A4 (en) * | 2017-03-10 | 2020-09-09 | Suzhou Kanova Biopharmaceutical Co., Ltd. | MONOCLONAL ANTIBODIES AGAINST BOTH IL-17A AND IL-17F AND USE THEREOF |
| GB201719447D0 (en) * | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| CN112513078B (zh) * | 2018-07-31 | 2022-11-18 | 沈为群 | 抗il-17a抗体及其用途 |
| CN110151999A (zh) * | 2019-05-22 | 2019-08-23 | 中国人民解放军第四军医大学 | 用于抑制恶性黑色素瘤进展的靶向药物 |
| AU2019456113A1 (en) * | 2019-07-11 | 2022-03-03 | Wuhan Yzy Biopharma Co., Ltd. | Tetravalent symmetric bispecific antibody |
| GB201919061D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| WO1990002809A1 (en) | 1988-09-02 | 1990-03-22 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991016353A1 (en) | 1990-04-23 | 1991-10-31 | Corvas International N.V. | Thrombus-specific antibody derivatives |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| NZ251956A (en) | 1992-04-27 | 1995-08-28 | Commw Of Australia | Optimum estimation of parameters defining a communications link |
| US6274711B1 (en) | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
| EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
| ATE243745T1 (de) | 1994-01-31 | 2003-07-15 | Univ Boston | Bibliotheken aus polyklonalen antikörpern |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| EP0839196B1 (en) | 1995-07-19 | 2005-05-11 | Genetics Institute, LLC | Human ctla-8 and uses of ctla-8-related proteins |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| AU2559799A (en) | 1998-01-22 | 1999-08-09 | Genentech Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same |
| EP1053751A1 (en) | 1999-05-17 | 2000-11-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods for treating cell proliferation disorders |
| US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| ATE482719T1 (de) | 2002-02-21 | 2010-10-15 | Univ Duke | Behandlungsverfahren unter verwendung von anti- cd22-antikörpern |
| EP1570267B1 (en) | 2002-12-03 | 2011-10-12 | UCB Pharma, S.A. | Assay for identifying antibody producing cells |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| SI1644412T2 (sl) | 2003-07-01 | 2018-11-30 | Ucb Biopharma Sprl | Modificirani fab fragmenti protiteles |
| NZ544317A (en) | 2003-07-08 | 2009-05-31 | Genentech Inc | IL-17 A/F heterologous polypeptides and therapeutic uses thereof |
| EP2974742A1 (en) | 2003-11-21 | 2016-01-20 | UCB Biopharma SPRL | Method for the treatment of multiple sclerosis by inhibiting il-17 activity |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| JP2008526205A (ja) | 2004-12-31 | 2008-07-24 | ジェネンテック・インコーポレーテッド | Ｂｒ３に結合するポリペプチド及びその使用 |
| EP1848743A2 (en) | 2005-02-14 | 2007-10-31 | Wyeth | Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor |
| JP2008532493A (ja) | 2005-02-14 | 2008-08-21 | ワイス | Ｉｌ−１７ｆとｉｌ−１７ｒとの間の相互作用の特性解析 |
| ES2353117T3 (es) * | 2005-09-28 | 2011-02-25 | Zymogenetics, Inc. | Antagonistas de il-17a e il-17f y métodos de uso de los mismos antagonistas de il-17a e il-17f y métodos de uso de los mismos. |
| PT1963368E (pt) | 2005-12-13 | 2012-09-14 | Lilly Co Eli | Anticorpos anti-il-17 |
| US20070218065A1 (en) | 2006-03-10 | 2007-09-20 | Jaspers Stephen R | Antibodies that bind both il-17a and il-17f and methods of using the same |
| US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| ATE530578T1 (de) | 2006-08-11 | 2011-11-15 | Schering Corp | Antikörper gegen il-17a |
| GB0620729D0 (en) * | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| TW200902064A (en) | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
| ES2463482T3 (es) | 2007-04-27 | 2014-05-28 | Zymogenetics, Inc. | Anticuerpos que se unen a IL-17a y a IL-17f y procedimientos de uso de los mismos |
| WO2008134659A2 (en) | 2007-04-27 | 2008-11-06 | Zymogenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
| CN101842387B (zh) | 2007-09-26 | 2014-05-07 | Ucb医药有限公司 | 双特异性抗体融合物 |
| GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
| KR101508086B1 (ko) | 2008-05-05 | 2015-04-07 | 노비뮨 에스 에이 | 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법 |
| US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
| CN105601745B (zh) | 2008-09-26 | 2020-09-08 | Ucb医药有限公司 | 生物产品 |
| ES2542903T3 (es) | 2009-07-14 | 2015-08-12 | Wavetec Vision Systems, Inc. | Sistema de medición para cirugía oftálmica |
| WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| ES2632583T3 (es) | 2011-01-14 | 2017-09-14 | Ucb Biopharma Sprl | Anticuerpo que se une a IL-17A e IL-17F |
-
2012
- 2012-01-11 ES ES12700433.1T patent/ES2632583T3/es active Active
- 2012-01-11 MY MYPI2013701205A patent/MY162790A/en unknown
- 2012-01-11 SI SI201230994T patent/SI2663577T1/sl unknown
- 2012-01-11 LT LTEP12700433.1T patent/LT2663577T/lt unknown
- 2012-01-11 EP EP17163570.9A patent/EP3219728A1/en not_active Withdrawn
- 2012-01-11 DK DK12700433.1T patent/DK2663577T3/en active
- 2012-01-11 KR KR1020137021367A patent/KR101950306B1/ko active IP Right Grant
- 2012-01-11 PT PT127004331T patent/PT2663577T/pt unknown
- 2012-01-11 CA CA2823812A patent/CA2823812C/en active Active
- 2012-01-11 PL PL12700433T patent/PL2663577T3/pl unknown
- 2012-01-11 ME MEP-2017-146A patent/ME02734B/me unknown
- 2012-01-11 RS RS20170705A patent/RS56298B1/sr unknown
- 2012-01-11 SG SG10201510762YA patent/SG10201510762YA/en unknown
- 2012-01-11 WO PCT/GB2012/050050 patent/WO2012095662A1/en active Application Filing
- 2012-01-11 SG SG2013052741A patent/SG191906A1/en unknown
- 2012-01-11 EA EA201300819A patent/EA037071B1/ru unknown
- 2012-01-11 MA MA36181A patent/MA34907B1/fr unknown
- 2012-01-11 AU AU2012206431A patent/AU2012206431B2/en active Active
- 2012-01-11 CN CN201280009581.4A patent/CN103384682B/zh active Active
- 2012-01-11 EP EP12700433.1A patent/EP2663577B1/en active Active
- 2012-01-11 JP JP2013548889A patent/JP6028737B2/ja active Active
- 2012-01-11 BR BR112013017951-1A patent/BR112013017951B1/pt active IP Right Grant
- 2012-01-11 US US13/348,456 patent/US8580265B2/en active Active
- 2012-01-11 MX MX2013007956A patent/MX341489B/es active IP Right Grant
- 2012-01-12 AR ARP120100115A patent/AR084845A1/es active IP Right Grant
- 2012-01-12 TW TW101101182A patent/TWI511978B/zh active
- 2012-11-01 UA UAA201309003A patent/UA110358C2/ru unknown
-
2013
- 2013-07-04 IL IL227347A patent/IL227347B/en active IP Right Grant
- 2013-07-10 TN TNP2013000292A patent/TN2013000292A1/fr unknown
- 2013-07-12 CL CL2013002044A patent/CL2013002044A1/es unknown
- 2013-08-12 CO CO13191259A patent/CO6781516A2/es not_active Application Discontinuation
- 2013-08-13 ZA ZA2013/06080A patent/ZA201306080B/en unknown
- 2013-11-08 US US14/074,880 patent/US9034600B2/en active Active
-
2015
- 2015-04-20 US US14/690,892 patent/US9988446B2/en active Active
-
2016
- 2016-10-03 JP JP2016195952A patent/JP2017046699A/ja active Pending
-
2017
- 2017-07-05 HR HRP20171034TT patent/HRP20171034T1/hr unknown
- 2017-07-12 CY CY20171100738T patent/CY1119055T1/el unknown
-
2018
- 2018-05-08 US US15/974,407 patent/US20180346561A1/en not_active Abandoned
-
2020
- 2020-12-15 US US17/122,752 patent/US11919950B2/en active Active
-
2022
- 2022-01-04 FR FR22C1000C patent/FR22C1000I2/fr active Active
- 2022-01-10 HU HUS2200001C patent/HUS2200001I1/hu unknown
- 2022-01-12 FI FIC20220002C patent/FIC20220002I1/fi unknown
- 2022-01-19 LT LTPA2022501C patent/LTPA2022501I1/lt unknown
- 2022-01-19 NL NL301159C patent/NL301159I2/nl unknown
- 2022-12-21 AR ARP220103527A patent/AR128047A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301159I2 (nl) | bimekizumab | |
| DK2744810T4 (da) | Tenofovir-alafenamid-hemifumarat | |
| DK2769050T3 (da) | Propsensor | |
| BR112014000879A2 (pt) | deflegmador | |
| DK3272861T3 (da) | Alpha-galactosidase-sammensætninger | |
| CO6960543A2 (es) | 2-tiopirimidinonas | |
| DE102011100082A8 (de) | Traygreifvorrichtung | |
| DK3141251T3 (da) | Koloskopi - forberedelse | |
| DE112011104936A5 (de) | Stanzstauchniet | |
| DE112012000958A5 (de) | Handsäge | |
| DK2476953T3 (da) | Fluidbedkedel | |
| DE112012002458A5 (de) | Hydrotransformator | |
| DE112012000819A5 (de) | Gurtbandfänger | |
| DE112012005313A5 (de) | Leuchtbild | |
| DK2526750T3 (da) | Høbjærgningsmaskine | |
| DE112012001294T8 (de) | Umspritzungsverfahren | |
| DE102011117169A8 (de) | Absetzplattenanordnung | |
| DE112011105396A5 (de) | Nachverfestigungsverfahren | |
| DK2681057T3 (da) | Nanofiber-mærkning | |
| ES1076319Y (es) | Minisalvavidas acuatico | |
| ES1075696Y (es) | Calzoncillo | |
| ES1075978Y (es) | Cucharon-colador-trasvasador | |
| ES1075621Y (es) | Minialetas | |
| FI20110369A0 (fi) | Neppariverhokiinnitys | |
| FI20110362A0 (fi) | Kylmägeelimatto |